Burkitt's lymphoma: The Rosetta Stone deciphering Epstein-Barr virus biology  by Rowe, Martin et al.
RB
M
I
a
K
E
B
C
c
A
1
g
o
i
b
h
p
i
t
h
m
[
k
i
t
e
t
T
a
l
u
t
i
i
l
(
(
1
dSeminars in Cancer Biology 19 (2009) 377–388
Contents lists available at ScienceDirect
Seminars in Cancer Biology
journa l homepage: www.e lsev ier .com/ locate /semcancer
eview
urkitt’s lymphoma: The Rosetta Stone deciphering Epstein-Barr virus biology
artin Rowe ∗, Gemma L. Kelly, Andrew I. Bell, Alan B. Rickinson
nstitute for Cancer Studies, School of Cancer Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK
r t i c l e i n f o
eywords:
a b s t r a c tpstein-Barr virus
urkitt’s lymphoma
ancer pathogenesis
-myc
poptosis
Epstein-Barr virus was originally identiﬁed in the tumour cells of a Burkitt’s lymphoma, and was the ﬁrst
virus to be associated with the pathogenesis of a human cancer. Studies on the relationship of EBV with
Burkitt’s lymphoma have revealed important general principles that are relevant to other virus-associated
cancers. In addition, the impact of such studies on the knowledge of EBV biology has been enormous. Here,
we review some of the key historical observations arising from studies on Burkitt’s lymphoma that have
informed our understanding of EBV, and we summarise the current hypotheses regarding the role of EBV
rkitt’in the pathogenesis of Bu
. Introduction
Having characterised a childhood lymphoma that is endemic in
eographically restricted areas of equatorial Africa, Denis Burkitt
riginally hypothesized that this tumour might be caused by an
nsect-borne vector [1,2]. That hypothesis seemed to be borne out
y the subsequent discovery, by Epstein and co-workers, of a novel
erpesvirus in a tumour cell line established from a Burkitt’s lym-
homa (BL) patient [3]. There is now a substantial body of evidence
mplicating a role for this virus, the Epstein-Barr virus (EBV), in
he pathogenesis of most cases of BL (reviewed in [4]). EBV is not,
owever, an insect-borne agent. That role in BL belongs to Plas-
odium falciparum malaria, which is transmitted by mosquitoes
5]. Furthermore, the key event in the pathogenesis of BL is now
nown to be the acquisition of a chromosomal translocation, involv-
ng the immunoglobulin gene loci on chromosomes 14, 22 or 2 and
he c-myc oncogene on chromosome 8. This results in deregulated
xpression of the c-myc protein, and is a characteristic of all BL
umours including the minority that are not EBV-associated [6–8].
hrough mechanisms that are only partially understood, malaria
nd EBV together exert effects on the human host to increase the
ikelihood of this genetic accident, and to synergize with the dereg-
lated c-myc to enhance the survival and proliferative capacity of
he tumour.It has been suggested previously [9] that EBV is a metaphor-
cal Rosetta Stone for understanding the role of viruses in
mmunopathological disorders and human carcinogenesis. To a
arge extent, it is true that the association of EBV with malignant
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diseases has become paradigmatic for viral oncology. Conversely, it
is also the case that the study of BL has yielded many clues to the
biology of EBV. In this review we shall highlight some of the obser-
vations that have profoundly enhanced the wider understanding of
the interaction of EBV with normal and malignant cells.
2. EBV latent gene expression
Infection of resting primary B cells in culture leads to the estab-
lishment of growth-transformed lymphoblastoid cell lines (LCLs)
[10,11]. This potent growth-transforming property of EBV, together
with seroepidemiological data [12,13] and the demonstration of
EBV DNA in the tumours of nearly all African BL patients [14–16],
seemingly provided incontrovertible evidence for a role of EBV in
the pathogenesis of BL. A critical assumption was made, however,
that LCLs were good experimental models for the uncontrolled pro-
liferation of BL tumours. As methods became available to analyse
EBV gene expression in more detail, it was unexpectedly found
that BL tumours express a much more restricted pattern of viral
genes than do LCLs established from the normal B cells of the
same patients [17–19]. In fact, EBV-transformed LCLs are a better
model for B cell lymphoproliferations arising in immunosuppressed
patients [20–22], which underlines the different etiologies of two
EBV-associated tumours of B cell origin. The observation, that EBV
can establish different latent states (i.e. infections not leading to
replication of new virus particles) in normal and malignant B cells
[18,23,24], had repercussions for understanding the role of EBV not
only in BL, but also in other EBV-associated malignancies and in
normal persistence in healthy infected individuals (see below).
Open access under CC BY license. 2.1. Latency I and Latency III
More than 20 years after the ﬁrst realization that EBV gene
expression in BL cells differs from that in EBV-transformed normal
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Fig. 1. Patterns of EBV latent protein expression in different forms of viral latency. The top panel (A) is a schematic illustration of the EBV genome, showing the location of
coding exons for the nuclear antigens EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C and EBNA-LP; the viral bcl-2 homologue, BHRF1; and the three latent membrane proteins
LMP1, LMP2A and LMP2B. Also shown are the latent origin of replication (oriP), the BamHI W internal repeat region and the fusion of the terminal repeats (TR). Shown below (B)
are the structures of viral mRNA transcripts expressed in different forms of latency. Promoters are identiﬁed by arrowheads, coding exons are coloured and non-coding exons
are unshaded. Latency I, seen in most endemic BL tumours, is characterised by the restricted expression of a single latent antigen EBNA1 transcribed from Qp. The Latency
II form of infection seen in EBV-positive Hodgkin’s lymphoma and NPC tumour cells is characterised by expression of the LMP proteins in addition to Qp-initiated EBNA1.
The classical growth-transforming Latency III infection, displayed by in vitro-transformed LCLs, is characterised by expression of all ten latent cycle proteins; the different
EBNA mRNAs are generated by alternative splicing of long primary transcripts initiated either from the tandemly repeated Wp promoter or the upstream Cp promoter, while
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Weparate promoters in the BamHI N region transcribe the LMPs. BHRF1, which has
ranscripts in Latency III. A fourth type of infection, termed Wp-restricted latency, i
n the absence of EBNA2 and the LMPs, and is seen in a subset of endemic BL tumou
CLs, details are still emerging with the discovery of new forms of
atency [25,26], new latent genes [27], and several virally encoded
icro-RNAs [28–31].
It is now known that EBV transformed LCLs express at least
nuclear antigens (EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C
nd EBNA-LP) and three membrane proteins (LMP1, LMP2A and
MP2B); in contrast, the majority of BL tumours express only one
irally encoded protein, EBNA1. These two patterns of gene expres-
ion are often referred to as Latency III and Latency I, respectively
24], and they are achieved by the use of different promoters to gen-
rate alternative primary transcripts from which the different EBNA
RNAs are spliced (Fig. 1). In Latency I BL lines, EBNA1 transcripts
re driven by the Qp promoter in the BamHI Q region of the genome
32,33], whereas in Latency III LCLs the EBNA transcripts are driven
y either of two upstream promoters, Cp or Wp, in the BamHI C or
regions of the genome [34–37]. As we shall discuss later, expres-tly been described as a tenth latent antigen, is also expressed from Wp-initiated
acterised by expression of EBNA1, EBNA3A, EBNA3B, EBNA3C, EBNA-LP and BHRF1
ich carry EBV genomes deleted for the EBNA2 gene.
sion of the BHRF1 protein (a Bcl-2 homologue with anti-apoptotic
properties) is also associated with Latency III type infection, but is
not expressed in Latency I [27].
2.2. Latency II
An intermediate pattern of viral gene expression was originally
identiﬁed in undifferentiated nasopharyngeal carcinoma (NPC)
[38–40], and subsequently in EBV-associated gastric carcinomas
[41,42], Hodgkin’s lymphomas [43,44], and T cell lymphomas [45].
In this Latency II type of infection, transcripts for the LMP1 and
LMP2A/B proteins are expressed in addition to Qp-driven EBNA1,
and none of the other EBNAs is expressed (Fig. 1). It should be
noted that Latency II type infection deﬁnes a spectrum from EBNA1
expression with low levels of LMP2, typical of gastric carcinomas,
to EBNA1 expression with high levels of both LMP1 and LMP2 that
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s typical of Hodgkin’s lymphoma. Whilst B cells have the potential
o support any of these three types of latent infection, non-B cells
enerally display either a Latency I or Latency II type of infection.
his is due at least in part to the fact that activation of the Wp/Cp
romoters necessary for Latency III is regulated by a B cell-speciﬁc
ranscription factor, BSAP (alternatively called PAX-5) [46].
In growth-transformed B cells displaying Latency III type
nfection, LMP1 and LMP2A/B expression are dependent upon
xpression of EBNA2 [47–49], whereas in epithelial cells supporting
Latency II type infection, these membrane proteins are expressed
ndependently of EBNA2. Despite extensive study, the control of
he LMP genes in different latent states is not well understood.
ne contributory mechanism is the use of alternative promoters.
n B cells, expression of LMP1 and LMP2B in Latency III type infec-
ion is mediated by a bi-directional promoter that is proximal to
he LMP1 gene; this promoter, known as ED-L1p, is activated by
n EBNA2-dependent mechanism involving the transcription fac-
ors RBP-J, PU.1, POU, and AP-2 [47,50,51]. In epithelial cells a
istal LMP1 promoter, known as TR-L1p or ED-L1Ep, is activated
ndependently of EBNA2 via STAT3, Sp1 and Sp3 transcription fac-
ors [52–54]. However, the EBNA2-dependent expression of LMP1
n B cells and the EBNA2-independent expression in epithelial
ells cannot be explained simply by the use of different promot-
rs, since the proximal ED-L1p can be also activated in epithelial
ells, and LMP1-induced signalling pathways have been shown to
uto-activate LMP1 transcription from the ED-L1p independently of
BNA2 [55,56]. It should also be noted that the levels of LMP1 and
MP2 in Latency II type infection can be quite variable even within a
ype of malignancy. For example, whilst LMP2A transcripts are con-
istently expressed in NPC tumours, LMP1 transcripts are detected
n only a proportion of cases [38,39,57]. In this context, it may be
elevant that LMP2A expression has been reported to inhibit LMP1
ranscription in epithelial cells [58].
.3. Other types of latent infection in BL
At least two other types of latent gene expression are associated
ith BL. One, which involves expression of all six EBNAs but not
MP1 or LMP2, is probably very rare and may be a consequence of
ntegration of the viral genome into the cellular chromosome [59].
nother type of latent infection, in which all of the EBNAs except
BNA2 are expressed in the absence of LMP1 or LMP2 (Fig. 1), is
ore common and may be exhibited by more than 15% of endemic
L cases [25,26,59]. This latter type of latency arises because the
umours carry an episomal viral genome with a deleted sequence
hat removes the EBNA2 gene. For reasons that are not yet under-
tood, the Wp promoter rather than the Qp promoter is activated
or expression of EBNA transcripts, hence they are designated ‘Wp-
estricted latency’ BLs. Most importantly, the Wp-restricted latency
L cells express BHRF1, a viral protein not previously associated
ith latency [27]. This homologue of cellular Bcl-2 [60,61], was
reviously regarded as being a lytic cycle gene product but is reg-
larly expressed in Wp latency and confers a survival advantage
o the tumour cells [27]. EBNA2-deleted viruses can arise, albeit
arely, in cancer-free people [62,63] but since they cannot express
ssential transforming genes, these deleted viruses cannot replicate
y growth-transforming normal B cells and cannot therefore efﬁ-
iently colonize the normal B cell pool. That Wp-restricted latency
Ls are comparatively common amongst endemic BL tumours, sug-
ests that there must be some selection advantage during the
athogenesis of BL; this is despite the expression of immunodom-nant target antigens for CD8+ immune T cell responses such as
BNA3A, EBNA3B and EBNA3C. We shall return to this issue later in
he review.
Some BL tumours will successfully adapt to tissue culture and
stablish as cell lines. During early passages, EBV-positive BL linesBiology 19 (2009) 377–388 379
typically display the same pattern of EBV latency as the original
tumour in vivo, but during longer-term culture many lines drift
towards Latency III [18,23]. Concomitant with the broadening of
EBV latent gene expression, BL lines acquire a more differentiated
phenotype with a loss of germinal centre markers, such as CD10 and
Bcl-6, and an upregulation of activation markers, such as CD40 and
various adhesion molecules [18,23,64]. The drift of BL lines towards
Latency III is unlikely to be just an in vitro phenomenon, as immuno-
histochemical staining of some BL biopsies suggest that isolated
cells within a predominantly Latency I expressing tumour may in
fact express LMP1 and EBNA2 [65]. Why these Latency III cells do
not go on to dominate the tumour mass, could be a result of the
decreased rate of proliferation and the increased immunogenicity
of these cells [23,66,67].
The BARF1 protein is a second putative oncoprotein of EBV
[68,69]. Originally, BARF1 was thought to be exclusively an early
lytic cycle product, although there is now evidence that it can be
expressed during latency (e.g. [70,71]). BARF1 expression has been
detected in BL biopsies [70,72], NPC [73], and gastric cell carci-
noma [74]. In some of these studies it cannot be excluded that that
BARF1 expression is due to a small number of cells in lytic cycle, but
whether or not it is expressed in latency or in a small subpopulation
of cells in lytic cycle, BARF1 could still contribute to the malignant
phenotype since it is secreted as a soluble molecule.
2.4. Limitations of Latency nomenclature
The Latency I, II, III nomenclature was originally deﬁned on the
basis of the pattern of EBNA and LMP protein expression in BL and
EBV-transformed normal B cell lines [24]. Since EBNA1 is essen-
tial for replication and maintenance of the viral episome, the most
restricted form of latency possible in this system is Latency I. In
non-dividing cells, however, there is no longer a strict requirement
for EBNA1 expression. Consequently, a ‘Latency 0’ in which no viral
antigens are expressed is an additional option for asymptomatic
EBV persistence in healthy carriers.
An alternative nomenclature was recently suggested which has
the merit of simplifying EBV gene-expression patterns and ﬁt-
ting them into an elegant hypothesis for how EBV persists in the
healthy infected host [75]. In this alternative nomenclature, the
terms “growth program”, “default program” and “latency program”
roughly correspond to Latency III, Latency II, and Latency 0 (no
EBV protein expression), respectively. However, when the alter-
native nomenclature is applied to EBV-induced malignancies, it is
inadequate to cope with the complexity of EBV gene expression, a
situation that is exacerbated further as new patterns of EBV gene
expression are identiﬁed.
Whichever nomenclature is used, care must be taken to rec-
ognize their limitations. It would be inappropriate, for example,
to classify a tumour as Latency III when immunohistochemistry
showed that all the malignant cells were EBNA1+ but only rare
cells were also EBNA2+ and LMP1+. Analysis of the same tumour
sample by immuno-blot or by RT-PCR is inherently more prone to
misleading interpretations. Nevertheless, quantitative RT-PCR for
the complete range of latent genes in the tumour, and comparison
with expression in standard control cell lines, coupled with care-
ful analysis of Cp/Wp/Qp promoter usage, will usually indicate the
correct interpretation [76].
2.5. Non-coding RNA transcriptsIn addition to protein-coding transcripts, EBV generates abun-
dant non-coding transcripts (Fig. 2). The best studied are the RNA
polymerase III transcribed small non-polyadenylated RNAs, termed
EBER1 and EBER2, which are the most abundant viral transcripts in
latently infected cells [77–79]. Although it has been reported that
380 M. Rowe et al. / Seminars in Cancer Biology 19 (2009) 377–388
Fig. 2. Expression of non-coding EBV RNAs. Schematic illustration of the EBV genome showing the location of the non-coding EBER RNAs, BHRF1 miRNAs and BART miRNAs.
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(he non-coding nuclear EBER1 and EBER2 RNAs are transcribed by RNA polymera
egion gives rise to a family of highly spliced BamHI A rightward transcripts (BART
hese BART RNAs remains controversial, at least 21 miRNAs are generated from BA
hought to be generated from Wp/Cp-initiated transcripts. Also shown are the locati
ome lytically infected cells may not express EBERs [80], they are
bundantly expressed in all types of latent infection. Indeed, the
evels of EBERs are such that their detection by in situ hybridisation
s considered to be one of the most reliable indicators of latent EBV
nfection at the single cell level in normal and diseased tissues.
A complex cluster of non-polyadenylated RNAs map to the
amHI A region [40,81], and are collectively known as BARTs
BamHI A rightward transcripts). It is not clear whether these
ightward transcripts encode protein [82], but they do give rise
o several micro-RNA (miRNA) species. Mature miRNAs are small
about 21–24 nucleotides) single-stranded RNAs processed from
tem-loop containing double-stranded RNA precursors, and they
egulate gene expression by binding to complementary sequences
n the 3′ untranslated regions of target mRNAs to inhibit their trans-
ation or to direct their degradation [83]. It was ﬁrst reported in
004 that EBV encodes miRNAs [29]. They map to two regions of
he genome: the BamHI H region (EBV-miR-BHRF1s in 5′ and 3′
equences ﬂanking the BHRF1 open reading frame), and the BamHI
region (EBV-miR-BARTs, processed from the introns of the BARTs).
he virus encodes at least 3 EBV-miR-BHRF1 and 21 miR-BART
iRNAs [29–31,84]. Additional low-abundant species exist, mostly
rising from less efﬁcient processing of the complementary 5′ or 3′
rm of the short hairpin pre-miRNAs.
The BARTs are transcribed across a region of the viral genome
hich includes an 11.8 kbp sequence that is deleted in the prototype
95.8 EBV [85], thereby limiting B95.8 EBV to just 5 (miR-BART-1,
2, -3, -4, 15) of the 21 most abundant miRNAs from this region of
he genome. The miR-BARTs are expressed in all forms of latency
nd in lytic cycle. Some studies suggest that miR-BARTs are more
ighly expressed in epithelial cells than in B cells, and that in B
ells the miR-BARTs may be more highly expressed in Latency III
han in Latency I (e.g. [30,86–88]). However, accurate interpretation
f these data is difﬁcult because assays with different degrees of
ensitivity and quantitation have been used in different studies,
nd mostly with a small number of long-established cell lines.
In contrast to the miR-BARTs, the BamHI H-derived miRNAs
miR-BHRF1-1, 1-2 and 1-3) show a more restricted expressionnd are the most abundant viral transcripts in latently infected cells. The BamHI A
ich are also expressed in all forms of latency. While the protein-coding function of
A-derived introns. A second set of miRNAs, derived from the BamHI H region, are
he latent cycle proteins, latent origin of replication (oriP) and terminal repeats (TR).
pattern. BHRF1 transcripts in latent infection are mostly, if not
exclusively, activated from the Cp/Wp promoters [29,30] and, there-
fore, no miR-BHRF1s are detected in latently infected epithelial
tumours [88]. As for the miR-BARTs, the available evidence from
quantitative analysis of miR-BHRF1 expression in different types
of latency in B cell lines (e.g. [30,84,86]) does not yet allow con-
clusive inferences to be made with regards to a possible correlation
between the type of EBV latency and the expression of miR-BHRF1s.
In lytic cycle, BHRF1 transcripts initiate from a promoter proximal
to the BHRF1 open reading frame, and overlapping the miR-BHRF1-
1 sequence, so that only miR-BHRF1-2 and miR-BHRF1-3 can be
processed [30].
3. EBV gene expression and the pathogenesis of BL
The concept, that the ability of EBV to growth-transform nor-
mal B cells is directly responsible for the pathogenesis of BL, was
weakened by the demonstration that BL tumours have a more
restricted pattern of gene expression than EBV-transformed LCLs.
The validity of the concept was further questioned following a
series of studies with recombinant EBV lacking expression of indi-
vidual latent genes, which revealed that the loss of expression of
any one of EBNA1, EBNA2, EBNA3A, EBNA3C or LMP1 was sufﬁ-
cient to substantially or completely abrogate the ability to generate
LCLs following infection of primary B cells in culture (reviewed in
[89,90]).
It is generally accepted that deregulated expression of the c-myc
proto-oncogene, resulting from the chromosomal translocations
that are characteristic of all BLs, is the primary oncogenic event
in the pathogenesis of BL irrespective of the association with EBV.
What, then, is the role of EBV? There are two broad (and not mutu-
ally exclusive) hypotheses: (i) EBV might increase the likelihood
of genetic accidents giving rise to the translocation, and (ii) EBV
might complement the activity of c-myc. The fact that BL tumours
have phenotypic characteristics of germinal centre cells [91] pro-
vides one clue to the pathogenesis of BL that is supported by what
is known about two other co-factors for BL; malaria and HIV.
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In areas of endemic BL, an important co-factor with EBV for
ymphomagenesis is P. falciparum malaria (reviewed in [92]). Two
eatures of malarial infection likely to be relevant to BL are an
mmunosuppressive effect on EBV-speciﬁc T cell immunity [93–96],
nd a mitogenic effect on B cells [97,98]. The immunosuppressive
ffect may be responsible for the fact that children in areas of
oloendemic malaria have very high loads of EBV in the periph-
ral blood, and these levels are further elevated during acute
alarial infection [99–101]. The mitogenic effect of P. falciparum
alaria on B cells, leading to increased germinal centre activ-
ty, is also likely to be critical since BL displays many markers
f germinal centre cells and the c-myc/Ig gene translocations are
ikely to be accidents of immunoglobulin gene rearrangements
n the germinal centre. In normal circumstances, cells carrying
llicit immunoglobulin gene recombinations would be programmed
o self-destruct, but the elevated EBV loads in malarial patients
ould increase the likelihood of such cells being infected with
BV and rescued from cell death. Another major co-factor for BL,
s HIV. In contrast to malaria-associated BL, AIDS-associated BL
rises in patients who remain relatively immunocompetent [102].
IV patients do not show the same high EBV loads that are found
uring malarial infection, and only 30–40% of AIDS-associated
L tumours are EBV-positive. Similarly to malaria, however, HIV
nfection also activates the B cell system [103]. Together, these
bservations are consistent with a mechanism where increased ger-
inal centre activity is the critical factor for the generation of c-myc
ranslocations. The increased EBV load associated with malarial
nfections increases the likelihood that such cells will be rescued
rom the pro-apoptotic effects of activated c-myc by infection with
BV.
That EBV complements the functions of c-myc in BL, is consistent
ith experimental evidence (see below). Furthermore, if an acti-
ated c-myc is experimentally over-expressed in EBV-transformed
CLs, then proliferation of the cells becomes independent of EBNA2
nd LMP1. In addition, inhibition of EBNA2 function and, there-
ore, LMP1 expression causes the LCLs with activated c-myc to
ssume many of the phenotypic characteristics of BL lines [104,105].
ndeed, expression of the full Latency III set of EBV genes, particu-
arly EBNA2 and LMP1, appears to be incompatible with activated
-myc [105]. On the other hand, one or more of the restricted set of
enes expressed in BL appears to be able to complement activated
-myc in BL.
Over-expression of c-myc is a common feature of many can-
ers. It is a transcription factor that can bind to around 15% of
romoters on the human genome [106]. Consequently it inﬂuences
any facets of cell behaviour, including proliferation and apopto-
is (reviewed in [107]). In normal cells, c-myc expression is tightly
egulated and its functions that promote proliferation (including
pregulation of cyclin D and E, and downregulation of p27) are
ounterbalanced by c-myc-induced apoptotic checkpoints which
nclude the ARF/MDM2/p53 and RB pathways. Genes involved in
he p53 pathway are frequently mutated in BL (reviewed in [108]).
ore recently, animal models of c-myc induced tumours have
mplicated the pro-apoptotic BH3-only protein (Bim) as a p53-
ndependent apoptotic checkpoint [109,110].
Against this background, it is tempting to speculate that EBV
ight complement c-myc in BL by ablating the apoptotic activity
f the oncoprotein. Exactly how the EBV genes might effect this
omplementation is currently under investigation in a number of
aboratories, but one important clue is provided by observations on
im, which is downregulated in normal B cells following infection
nd growth-transformation with EBV in vitro [111]. Bim is highly
xpressed in Latency I BL but is substantially downregulated in Wp-
estricted BLs [27,112]. This suggests that downregulation of Bim
ight be a complementing factor in the Wp-restricted subset of BLs.
lthough downregulation of Bim is not seen in Latency I BLs, andBiology 19 (2009) 377–388 381
therefore is not likely to be involved in most cases of BL, the obser-
vation with Wp-restricted BLs does lend credence to the idea that
the pro-apoptotic checkpoints which regulate c-myc-induced pro-
liferation in normal cells are targeted by secondary genetic changes
and/or by EBV genes in the pathogenesis of BL.
3.1. EBV promotes survival and tumourigenicity in BL lines
What, then is the evidence that EBV might regulate apoptosis
pathways in BL? An important tool for answering this question
was provided by the fortuitous discovery that the maintenance of
the viral episome in some BL lines is unstable, so that it is pos-
sible to establish rare EBV-loss subclones in culture. EBV-positive
lines in Latency I show a small but reproducible survival advan-
tage over EBV-loss subclones when subjected to apoptotic triggers
[59,113,114]. The mechanism of this protection is not yet known,
even though the number of EBV genes potentially involved is
very limited. Interestingly, EBV-positive BL lines displaying a Wp-
restricted form of latency show a substantially enhanced protection
from apoptotic triggers [27,59,112].
3.2. Contribution of EBNA1 to BL
EBNA1 is expressed in all EBV-positive BLs. It is essential for
the replication of the EBV episome in proliferating cells [115,116].
In addition, the glycine-alanine repeat sequence of EBNA1 lim-
its its own translation efﬁciency and to some extent modulates
antigen processing to impair its own recognition by EBNA1-
speciﬁc CD8+ T cells [117,118]. While the episomal maintenance
and immune-modulating functions of EBNA1 are both relevant to
BL pathogenesis, they cannot themselves account for the enhanced
survival and tumourigenicity of EBV-positive BL lines relative to
rare subclones that have lost the EBV genome in culture. Neverthe-
less, EBNA1 appears to have additional functions. Thus, expression
of a dominant-negative mutant molecule in EBV-transformed LCLs
and in BL cells, to speciﬁcally inhibit the transcriptional functions of
EBNA1 while retaining the episome maintenance function, resulted
in a dose-dependent decrease in cell survival [119]. Conversely,
expression of EBNA1 in some EBV-negative lines was shown to
inhibit p53-dependent apoptosis [119].
3.3. Contribution of BARF1 to BL
BARF1 has been shown to enhance cell survival, clonability, and
tumourigenicity of EBV-loss subclones of the Akata BL line [120].
However, while the parental EBV-positive Akata cells expressed
abundant BARF1 transcripts, immunostaining for BARF1 protein
showed that it was actually expressed in only a small subpopula-
tion of cells; i.e. cells in lytic cycle. Furthermore, the anti-apoptotic
effect of BARF1 appears to be mediated via induced expression of
Bcl-2, which is not expressed in the parental EBV-positive Akata
cells nor in other Latency I BLs.
3.4. Contribution of EBERs to BL
The EBERs have been reported to restore a tumourigenic pheno-
type to BL cells that have lost the EBV genome in culture [121–123].
Through interaction with RIG-1 (retinoic acid-inducible gene-1),
the EBERs can induce anti-inﬂammatory cytokines, such as IL10
[124] and type I interferon production [125]. They may also con-
fer resistance to interferon- induced apoptosis through binding to
PKR (RNA-activated protein kinase) and inhibiting its phosphoryla-
tion [126,127]. The contribution of EBERs to the tumourigenicity of
BL lines is independent of the inhibition of PKR [122] but might be
related to induced expression of Bcl-2 [121]. It has been suggested
that EBERs induce expression of IL-10, which can act as an autocrine
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rowth factor to enhance survival of BL cells [128]. The generality of
ome of these observations is questioned by other studies: Bcl-2 is
ot normally expressed in BL tumours [129]; and cells infected with
BER-negative recombinant EBV or wild-type EBV did not differ in
heir sensitivity to interferon-mediated inhibition of proliferation
or the inhibitory effect of interferon on vesicular stomatitis virus
eplication [130]. Nevertheless, recombinant EBV lacking EBERs is
ess efﬁcient at transforming normal B cells [131]. In conclusion,
hilst the EBERs undoubtedly have the potential to inﬂuence cellu-
ar phenotype and immune-responses, the molecular mechanisms
nd their exact roles in the normal life-cycle of EBV and in the
athogenesis of EBV-associated malignancies remain unclear.
.5. Contribution of miRNAs to BL
The functions of some EBV miRNAs are beginning to be iden-
iﬁed, and their roles in EBV-associated malignancies may soon
e become apparent. The miR-BARTs are regularly expressed in
Ls, albeit often at lower levels than in EBV-associated epithe-
ial tumours. It should be noted, however, that the BARTs are not
ssential for EBV transformation of normal B cells to LCLs [132],
nd that a deletion in the prototype B95.8 strain of EBV removes
ost of the miR-BARTs [30] while retaining transformation func-
ion. In addition, the miR-BHRF1s may not be regularly expressed in
L tumours. Nevertheless, there remains the possibility that speciﬁc
BV miRNAs might enhance certain functions of EBV or c-myc in BL,
s EBV miRNAs have been shown to modulate expression of other
BV genes [133,134] as well as cellular genes [135,136]. Regarding
he regulation of cellular genes by EBV miRNAs, the effect of miR-
ART5 on PUMA (the p53 Up-regulated Modulator of Apoptosis)
s of immediate interest since PUMA regulates apoptosis via p53
ependent and independent mechanisms [136]. However, even in
PC where miR-BART5 is highly expressed [88,136], 40% of tumours
o not show a reduction in PUMA expression [136], suggesting that
n effect of miR-BART5 on cell survival through regulation of PUMA
s not a consistent feature of this NPC. Evidence for a role for EBV-
iRNAs in BL has yet to be reported.
.6. Contribution of BHRF1 and EBNA3 proteins to BL
The identiﬁcation of a subset of endemic BLs which carry EBV
n a Wp-restricted latency, and are concomitantly strongly resis-
ant to apoptotic triggers, adds further weight to the idea that the
ole of EBV in BL is to counteract the pro-apoptotic inﬂuence of
eregulated c-myc [25]. While a Latency I infection appears to pro-
ide low level protection from apoptotic triggers, the broadening
f viral antigen expression in Wp-restricted latency BLs to include
he viral Bcl2 homolog, BHRF1, and the EBNA3 family of proteins
s associated with much stronger protection from apoptosis and a
omplementation of c-myc induced lymphomagenesis [27,59,112].
The detection of BHRF1 expression in Wp-restricted BL cells,
esulting from the close proximity of the BHRF1 gene to the
ighly active BamHI W promoter as a consequence of the inter-
ening EBNA2-deleted sequences, provided a clear explanation for
heir survival advantage. BHRF1 is a Bcl2 homologue known to
e capable of protecting B cells from growth factor withdrawal,
RAIL death receptor signalling, irradiation and chemotherapeutic
rugs [61,137,138]. Until recently, however, BHRF1 expression was
hought to be restricted to the lytic replication cycle of EBV, and
ad not been detected in malignant cells. There is now growing evi-
ence that the two viral Bcl2 homologues encoded by EBV (BHRF1
nd BALF1) play important roles not only in lytic cycle, but also in
atently infected cells where they contribute to the initial stages of
rowth transformation [139] and possibly also, in the case of BHRF1,
o the continued growth or survival of EBV-transformed cells [27].
n the context of BL, it was shown that ectopic expression of lowBiology 19 (2009) 377–388
levels of BHRF1 in EBV-negative and Latency I BLs was sufﬁcient
to confer almost complete protection from ionomycin and anti-IgM
induced apoptosis, suggesting that the natural expression of BHRF1
in Wp-restricted BLs contributes to the enhanced resistance of this
subset of BLs to these apoptotic triggers [27].
A role for EBNA3A and EBNA3C together in apoptosis protec-
tion has also been reported and has implications for Wp-restricted
BL cells [140]. Here, EBV-negative BL cells were infected with
recombinant EBV genomes and, using drug selection, stable con-
verted cell lines were established. Although the BL phenotype
was not fully recapitulated since infection with recombinant EBV
genomes results in a Latency III-like infection with expression of
antigens not normally expressed in BL cells, such as EBNA2 and
LMP1, it was noted that BL cells infected with either EBNA3A-
deleted or EBNA3C-deleted recombinant EBVs were sensitized to
death induced with nocodazole, cisplatin or roscovitine [140].
This suggests that EBNA3A and EBNA3C can act co-operatively
to protect BL cells from these apoptotic triggers, and it reveals
a second mechanism through which EBV can complement c-
myc actions in BL lymphomagenesis. The relative contributions
of BHRF1 and EBNA3A/EBNA3C to Wp-restricted BL pathogenesis
will become clearer with detailed investigations into their mecha-
nisms of action, including the apoptotic pathways they inﬂuence.
Further investigations will also reveal to what extent BHRF1 and
EBNA3A/EBNA3C co-operate with, or mediate their effects through,
downregulation of Bim.
4. Immune modulating mechanisms in BL
T cell immune responses play an important role in prevent-
ing the outgrowth of EBV-transformed B cells in healthy infected
individuals (reviewed in [4]), but they are clearly ineffective at pre-
venting tumour growth in BL patients. To some extent, this may
be due to the immunosuppressive effects of P. falciparum malarial
infections in regions where BL is endemic [93,94,96], although the
potency of some EBV-speciﬁc EBV responses is restored following
recovery from an acute malarial attack [94]. More importantly, per-
haps, BL tumour cells display an inherent resistance to EBV-speciﬁc
CD8+ immune effectors [17,141,142].
The identiﬁcation of restricted Latency I EBV expression in BL
tumours offered a simple explanation for the resistance to CD8+ T
cell responses. The repression of immunodominant viral target anti-
gens [143,144] that are expressed in LCLs, and the partial protection
offered to EBNA1 by its glycine-alanine domain [117,118,145] would
surely enable these tumours to evade immune responses? More
recent studies have questioned the extent to which the processing
defect of EBNA1 might render this protein immunologically silent
[146–148]. Furthermore, Wp-restricted BLs (which do express the
immunodominant EBNA3A, 3B, 3C family of latent genes) are also
poorly recognized by CD8+ immune effectors [25]. This latter result
in particular highlights the fact that BL cells have a more general
impairment of antigen presenting function irrespective of EBV sta-
tus. Notably, BL cells express reduced levels of adhesion molecules
[64] that are required for efﬁcient conjugate formation with effec-
tor T cells, and of HLA class I molecules [19,141,142] which present
antigenic peptides at the cell surface for recognition by the T cell
receptor of CD8+ effector T cells. In addition to a general reduc-
tion in cell surface HLA class I molecules, certain HLA alleles are
selectively downregulated to a greater degree [149]. BL cells also
show reduced levels of the TAP1/TAP2 transporter complex [67,150]
which mediates transport of antigenic peptides from the cytosol to
the ER where they associate with MHC class I molecules. Together,
these features of the BL cell phenotype render the tumour cells
resistant to CD8+ effector T cell recognition even when appropri-
ate endogenous target antigens are expressed. This resistance is
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Fig. 3. Selective colonization of the memory B cell compartment during primary EBV infection. How EBV achieves selective colonization of the isotype class-switched
memory B cell pool in vivo remains unclear. One hypothesis [75] proposes that incoming virions preferentially infect IgM+IgD+ naïve B cells which, as a result of a transient
growth-transforming infection mimicking antigen stimulation, are driven to form a germinal centre (GC). Thereafter the physiologic processes of somatic hypermutation and
class switch recombination come into play and deliver latently infected IgG+CD27+ or IgA+CD27+ GC progeny cells into the long-lived memory compartment. An alternative
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nvisages the preferential infection and/or survival of memory cells post-infection,
hare one key feature; that downregulation of viral antigen expression is linked to t
eversible following expression of LMP1, which upregulates expres-
ion of the adhesion molecules, TAP1/TAP2 transporters and HLA
lass I molecules [67,151,152].
The effect of the BL tumour phenotype on HLA class II anti-
en presentation is less well studied. Early work showed that the
bility of BLs to process antigen via HLA class II and stimulate
D4+ T cell responses was impaired in BL tumour lines [153]. More
ecent work, however, shows that BL cells can be killed by EBNA1-
peciﬁc CD4+ effector T cells [154], and Wp-restricted BLs can
resent EBNA3C epitopes to CD4+ T cells [155]. Such CD4+ immune
esponses to EBNA1 appear to be relatively common in healthy
nfected individuals, and an animal model demonstrated that these
mmune responses are potentially able to prevent the growth of
L tumours in vivo [156]. Interestingly, however, EBNA1-speciﬁc
D4+ responses are selectively impaired in children with endemic
L [157].
. Lessons from BL for the biology of EBV
BL was the ﬁrst well-documented example of a human tumour
howing a consistent impairment of antigen presenting function
19,67,142,150] and has become a paradigm for immune-escape by
umour cells of both viral and non-viral associated cancers. There is
lso the possibility that defects in HLA class I antigen presentation
n BL and other cancers might directly enhance tumour growth by
ffording protection from apoptotic stimuli [158].
One important lesson from studies on BL lymphoma was that
either the viral gene expression nor the cellular phenotype is
unique feature of malignant cells. This was speculated before
estricted forms of latency were identiﬁed in long-term healthy
arriers [159–162], and before the cell surface marker expression
f BL tumour cells was shown to have a normal counterpart in the
erminal centre [91].leosis lymphoid tissues [184], questions the involvement of GC transit and instead
red to their naïve counterparts. These models are not mutually exclusive, and both
rmal differentiation of B cells.
This lesson, together with the observation that the virus:cell
interaction in BL was effectively immunologically silent for CD8+
T cell responses (see previous section), provided the foundation for
our current understanding of how EBV normally colonizes the B
cell compartment and persists in healthy carriers (Fig. 3). Thorley-
Lawson’s group has been particularly active in elucidating the
mechanisms of EBV persistence, and one of their key observations
was that EBV-infected cells in the blood of long-term carriers are
conﬁned to the memory B cell subset and are absent from the
larger, naïve B cell subset [163,164]. This led to the development
of a model for EBV colonization of the B cell pool which reﬂects the
normal physiological process of normal B cell development [75]
and is broadly supported by a large body of evidence from the
Thorley-Lawson group and others. The fact that LMP1 can reverse
the antigen presentation defect in BL tumour cells [67] suggests that
this viral oncoprotein provides an immunological check to counter
the uncontrolled growth of LCL-like cells in immunocompetent
infected individuals. In long-lived memory B cells carrying EBV as
a latent infection in vivo, the cells do not need to proliferate and so
they can support the more restricted types of latency where criti-
cal transformation-associated latent genes are not expressed [162],
and where there is no need for LMP1 to enhance immunogenicity.
A corollary of the hypothesis for EBV persistence in normal car-
riers is that the stage of B cell development determines EBV gene
expression and that mechanisms must exist for switching infected
cells between different forms of latency. There is undoubtedly a
correlation between EBV gene expression and cellular gene expres-
sion both in normal and in malignant cells, although most studies
have used experimental models that demonstrate EBV genes driv-
ing the cellular phenotype, rather than vice versa. Thus, transfection
of individual EBV latent genes, particularly LMP1 and EBNA2 into
primary B cells or EBV-negative or Latency I BL cells drives the cellu-
lar phenotype towards a more differentiated activated lymphoblast
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henotype (reviewed in [90]). Reversal of the lymphoblastoid phe-
otype in a conditional LCL model to a germinal centre phenotype
an be achieved by inhibiting the function of EBNA2, and thus
lso the expression of LMP1, provided that activated c-myc is con-
titutively expressed [105]. There is, however, also evidence to
upport the view that the cellular phenotype can determine EBV
ene expression. For example, activation of the Wp and Cp pro-
oters immediately following infection of resting B cells in vitro is
ependent upon expression of the BSAP/PAX-5 transcription factor
hose expression is B cell speciﬁc [46], and the silencing of latent
ene promoters can occur by epigenetic mechanisms mediated by
ellular genes [165–171]. Furthermore, infection of chronic lym-
hocytic leukaemia B cells with EBV in vitro results in an unusual
ype of latent gene expression where the EBNAs are expressed in
he absence of LMPs and the cells are not growth-transformed
172,173], whereas prolymphocytic leukaemia B cells express the
ull Latency III spectrum of EBV genes and are transformed [173].
nfection of an EBV-negative Hodgkin’s lymphoma cell line (KMH2),
hich has germinal centre characteristics, results in a Latency I or
atency II type of EBV gene expression [174,175]. The mechanisms
y which the differentiation state of the host B cell determines viral
ene expression remain to be elucidated, but this information is
ritical for a more complete understanding of the normal carrier
tate.
The impairment of HLA class I antigen presentation in BL
rovides an explanation for how BL tumours grow in the face
f relatively intact T cell responses, and the enhancement of
ntigen presentation in Latency III type infection might explain
hy immunocompetent long-term carriers of EBV do not usually
uccumb to B cell lymphoproliferations arising from growth-
ransformation of normal B cells. Until recently, the enhanced
ntigen presentation of normal primary B cells following infec-
ion in vitro suggested that EBV was somewhat distinct from other
erpesviruses which encoded genes that directly interfered with
ntigen presentation. However, the immune-modulating genes of
ther herpes viruses are generally expressed during lytic cycle, and
e now know that EBV similarly encodes immune evasion genes
uring its own lytic cycle. Thus, immune recognition of EBV tar-
et antigens during lytic cycle is impaired through BGLF5, BNLF2a,
ILF1 (vGPCR), and BCRF1 (vIL10) acting at different points of the
LA class I antigen presentation pathway, and BZLF1, BZLF2 and
GLF5 acting on the HLA class II antigen presentation pathway
reviewed in [176]). This highlights a point that although lytic cycle
ene products are the most frequent targets for EBV-speciﬁc CD8+
mmune-T cells in healthy carriers, it does not necessarily follow
hat those responses effectively eliminate infected cells that have
ntered lytic cycle. In fact, NK cells might be more important for
reventing the excessive production of virus progeny in primary
nfection and healthy carriers [177,178].
Another key lesson from BL was that protection from apoptosis,
hich is important for the growth of this tumour, can be induced
y EBV latent genes [179]. The ﬁrst EBV gene that was identiﬁed as
aving anti-apoptotic properties was LMP1, which acts by inducing
he anti-apoptotic proteins, Bcl-2, Mcl-1, and bﬂ-1 [129,180,181]. To
arying extents, EBNA2 [182], LMP2A [183] and EBNA3A/C [140] can
lso enhance cell survival. These latent gene products are all essen-
ial for the ability of EBV to growth-transform primary B cells. This
ndicates that EBV-induced growth transformation is not simply a
atter of triggering proliferation by activating cell cycle, but criti-
ally it also involves modulation of apoptosis pathways to enhance
ell survival. With regards to BL, the latent genes LMP1, LMP2A,
nd EBNA2 are not normally expressed in the tumour cells, yet EBV
oes confer a survival advantage in Latency I BLs; particularly so
n Wp-restricted Latency BLs. The study of Wp-restricted BLs has
ighlighted an important role for BHRF1, both as a contributor to the
athogenesis of a subset of BL tumours and also as a gene involvedBiology 19 (2009) 377–388
in the establishment of in vitro transformed LCLs. Altmann and
Hammerschmidt showed that immediate inhibition of apoptosis
is an essential requirement following in vitro infection of primary B
cells and that the two viral homologues of Bcl-2, BHRF1 and BALF1,
were transiently expressed during the early stages of transforma-
tion [139]. This remarkable result was unexpected since both BHRF1
and BALF1 were considered to be lytic cycle genes. Their expres-
sion was attributed to promiscuous expression of the unmethylated
EBV genome shortly after viral entry. However, more recent results
[27] show that latent BHRF1 transcripts are driven from the Wp-
promoter so that this protein is co-expressed with EBNA-LP and
EBNA2 shortly after infection. Furthermore, low levels of BHRF1
protein continue to be expressed in some established LCLs where
some Wp promoter activity is retained.
From the examples illustrated here, it is clear that the study of
BL has provided us with invaluable clues to the biology of EBV
in asymptomatic carriers and to its association with malignant
disease. EBV and BL have together provided paradigms for under-
standing the intricate interactions of viruses and tumours with the
immune system. Fascinatingly, this well-worn model continues to
surprise us with new details that have important implications for
EBV and the wider ﬁeld of viral oncology.
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